Search results for "Therapeutic resistance"

showing 5 items of 5 documents

Dual disruption of aldehyde dehydrogenases 1 and 3 promotes functional changes in the glutathione redox system and enhances chemosensitivity in nonsm…

2020

AbstractAldehyde dehydrogenases (ALDHs) are multifunctional enzymes that oxidize diverse endogenous and exogenous aldehydes. We conducted a meta-analysis based on The Cancer Genome Atlas and Gene Expression Omnibus data and detected genetic alterations in ALDH1A1, ALDH1A3, or ALDH3A1, 86% of which were gene amplification or mRNA upregulation, in 31% of nonsmall cell lung cancers (NSCLCs). The expression of these isoenzymes impacted chemoresistance and shortened survival times in patients. We hypothesized that these enzymes provide an oxidative advantage for the persistence of NSCLC. To test this hypothesis, we used genetic and pharmacological approaches with DIMATE, an irreversible inhibito…

Male0301 basic medicineCancer ResearchLung NeoplasmsCell- och molekylärbiologiCellAldehyde dehydrogenaseKaplan-Meier EstimateMicechemistry.chemical_compound0302 clinical medicineCarcinoma Non-Small-Cell LungAntineoplastic Combined Chemotherapy ProtocolsCytotoxicityMiddle AgedAldehyde OxidoreductasesGlutathioneCancer metabolismUp-Regulation3. Good healthCancer therapeutic resistancemedicine.anatomical_structureAlkynes030220 oncology & carcinogenesisFemale[SDV.CAN]Life Sciences [q-bio]/CancerBiologyIsozymeAldehyde Dehydrogenase 1 FamilyArticle03 medical and health sciencesTargeted therapiesDownregulation and upregulationCell Line TumorGeneticsmedicineAnimalsHumansSulfhydryl CompoundsLung cancerMolecular BiologyAgedCancer och onkologiGene AmplificationRetinal DehydrogenaseGlutathioneAldehyde Dehydrogenasemedicine.diseaseXenograft Model Antitumor AssaysALDH1A1030104 developmental biologychemistryDrug Resistance NeoplasmCancer and Oncologybiology.proteinCancer researchCisplatinReactive Oxygen SpeciesCell and Molecular Biologynonsmall cell lung cancer
researchProduct

Hypoxia, Lactate Accumulation, and Acidosis: Siblings or Accomplices Driving Tumor Progression and Resistance to Therapy?

2013

This chapter briefly summarizes the most important processes by which hypoxia, lactate accumulation, and acidosis may influence malignant progression and therapeutic resistance of solid malignant tumors. While these phenomena are often elements of an integrated reaction, they may occur independently of each other under certain circumstances. The latter information may be of interest with regard to possible “targeted” therapeutic interventions.

Pathologymedicine.medical_specialtyHypoxic tumorTumor progressionmedicineCancer researchHypoxia (medical)medicine.symptomMalignant progressionBiologyTherapeutic resistanceStem cell phenotypeAcidosis
researchProduct

Tumor hypoxia and therapeutic resistance

2008

For many years, the identification of tumor hypoxia, its systematic characterization and the assessment of its clinical relevance were not possible due to the lack of methods suitable for the routine measurement of intratumoral oxygen tensions in patients. In the late 1980s, a novel and clinically applicable standardized procedure was established enabling the determination of tumor oxygenation in accessible primary tumors, local recurrences, and metastatic lesions in patients using a computerized polarographic needle electrode system (Vaupel et al. 1991; Hockel et al. 1991). Within a relatively short period of time, the significance of tumor oxygenation for therapy outcome became evident in…

Therapy OutcomeOncologyNeedle electrodemedicine.medical_specialtyMetastatic lesionsTumor hypoxiabusiness.industryTherapeutic resistanceTumor OxygenationInternal medicineMedicineClinical significanceIn patientbusiness
researchProduct

MTOR inhibitor-based combination therapies for pancreatic cancer

2018

Background: Although the mechanistic target of rapamycin (MTOR) kinase, included in the mTORC1 and mTORC2 signalling hubs, has been demonstrated to be active in a significant fraction of patients with pancreatic ductal adenocarcinoma (PDAC), the value of the kinase as a therapeutic target needs further clarification. Methods: We used Mtor floxed mice to analyse the function of the kinase in context of the pancreas at the genetic level. Using a dual-recombinase system, which is based on the flippase-FRT (Flp-FRT) and Cre-loxP recombination technologies, we generated a novel cellular model, allowing the genetic analysis of MTOR functions in tumour maintenance. Cross-species validation and pha…

therapeutic resistance0301 basic medicineCancer ResearchCell SurvivalMAP Kinase Signaling Systempancreatic cancerAntineoplastic AgentsContext (language use)Mechanistic Target of Rapamycin Complex 2mTORC1Mechanistic Target of Rapamycin Complex 1BiologymTORC2BortezomibMice03 medical and health sciencesCell Line TumorPancreatic cancermedicineAnimalsHumansExtracellular Signal-Regulated MAP KinasesMechanistic target of rapamycinPI3K/AKT/mTOR pathwayBenzoxazolesKinaseMTORTOR Serine-Threonine Kinasesmedicine.diseaseddc:3. Good healthPancreatic NeoplasmsPyrimidines030104 developmental biologyOncologybiology.proteinCancer researchCamptothecinTOR Serine-Threonine KinasesPhosphatidylinositol 3-KinaseTranslational TherapeuticsProto-Oncogene Proteins c-aktBiologieCarcinoma Pancreatic Ductal
researchProduct

Heat Shock Protein 60 in Hepatocellular Carcinoma: Insights and Perspectives

2020

Heat shock protein 60 (HSP60) is a mitochondrial chaperone that is implicated in physiological and pathological processes. For instance, it contributes to protein folding and stability, translocation of mitochondrial proteins, and apoptosis. Variations in the expression levels of HSP60 have been correlated to various diseases and cancers, including hepatocellular carcinoma (HCC). Unlike other HSPs which clearly increase in some cancers, data about HSP60 levels in HCC are controversial and difficult to interpret. In the current review, we summarize and simplify the current knowledge about the role of HSP60 in HCC. In addition, we highlight the possibility of its targeting, using chemical com…

therapeutic resistancechaperoninanimal structureslcsh:Biology (General)fungiheat shock proteinscancer therapychaperoneschemical and pharmacologic phenomenahepatocellular carcinomacomplex mixtureslcsh:QH301-705.5digestive system diseasesFrontiers in Molecular Biosciences
researchProduct